These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 20189244)
1. In vitro and in vivo performance of a dual drug-eluting stent (DDES). Huang Y; Venkatraman SS; Boey FY; Lahti EM; Umashankar PR; Mohanty M; Arumugam S; Khanolkar L; Vaishnav S Biomaterials; 2010 May; 31(15):4382-91. PubMed ID: 20189244 [TBL] [Abstract][Full Text] [Related]
2. The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model. Huang Y; Venkatraman SS; Boey FY; Umashankar PR; Mohanty M; Arumugam S J Interv Cardiol; 2009 Oct; 22(5):466-78. PubMed ID: 19627432 [TBL] [Abstract][Full Text] [Related]
4. The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer. Lee YK; Hyung Park J; Tae Moon H; Yun Lee D; Han Yun J; Byun Y Biomaterials; 2007 Mar; 28(8):1523-30. PubMed ID: 17157376 [TBL] [Abstract][Full Text] [Related]
5. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study. Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312 [TBL] [Abstract][Full Text] [Related]
6. Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent. Xu B; Zhang Q; Yang YJ; Qiao SB; Zhang RY; Zhang JS; Hu J; Qin XW; Hong T; Li JP; Chen JL; Huo Y; Gao RL; Shen WF Chin Med J (Engl); 2008 Mar; 121(6):492-7. PubMed ID: 18364131 [TBL] [Abstract][Full Text] [Related]
7. Drug-eluting coronary stents: many meta-analyses, little benefit. Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298 [TBL] [Abstract][Full Text] [Related]
9. The characteristics and in vivo suppression of neointimal formation with sirolimus-eluting polymeric stents. Chen MC; Chang Y; Liu CT; Lai WY; Peng SF; Hung YW; Tsai HW; Sung HW Biomaterials; 2009 Jan; 30(1):79-88. PubMed ID: 18838155 [TBL] [Abstract][Full Text] [Related]
10. The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Steigerwald K; Merl S; Kastrati A; Wieczorek A; Vorpahl M; Mannhold R; Vogeser M; Hausleiter J; Joner M; Schömig A; Wessely R Biomaterials; 2009 Feb; 30(4):632-7. PubMed ID: 18990438 [TBL] [Abstract][Full Text] [Related]
11. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents. Grube E; Buellesfeld L Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588 [TBL] [Abstract][Full Text] [Related]
12. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Jabara R; Chronos N; Robinson K Catheter Cardiovasc Interv; 2008 Aug; 72(2):186-94. PubMed ID: 18651646 [TBL] [Abstract][Full Text] [Related]
13. Improved blood compatibility of rapamycin-eluting stent by incorporating curcumin. Pan CJ; Tang JJ; Shao ZY; Wang J; Huang N Colloids Surf B Biointerfaces; 2007 Sep; 59(1):105-11. PubMed ID: 17540543 [TBL] [Abstract][Full Text] [Related]
14. Experimental efficacy of an everolimus eluting cobalt chromium stent. Carter AJ; Brodeur A; Collingwood R; Ross S; Gibson L; Wang CA; Haller S; Coleman L; Virmani R Catheter Cardiovasc Interv; 2006 Jul; 68(1):97-103. PubMed ID: 16755598 [TBL] [Abstract][Full Text] [Related]
15. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311 [TBL] [Abstract][Full Text] [Related]
16. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents? Zhao FH; Chen YD; Jin ZN; Lu SZ Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856 [TBL] [Abstract][Full Text] [Related]
17. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798 [TBL] [Abstract][Full Text] [Related]
19. Drug-eluting stents and stent thrombosis: a cause for concern? Wernick MH; Jeremias A; Carrozza JP Coron Artery Dis; 2006 Dec; 17(8):661-5. PubMed ID: 17119373 [TBL] [Abstract][Full Text] [Related]
20. Fabrication and characteristics of dual functionalized vascular stent by spatio-temporal coating. Kim SM; Park KS; Lih E; Hong YJ; Kang JH; Kim IH; Jeong MH; Joung YK; Han DK Acta Biomater; 2016 Jul; 38():143-52. PubMed ID: 27109766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]